A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
about
Fixed-dose combination therapy for the prevention of cardiovascular diseaseMultifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular PolypillThe gastro-esophageal malignancies in Northern Iran research project: impact on the health research and health care systems in IranCharacteristics of high risk people with cardiovascular disease in Chinese rural areas: clinical indictors, disease patterns and drug treatmentUse of medications and lifestyles of hypertensive patients with high risk of cardiovascular disease in rural ChinaFixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in ZhejiangRenal function and risk factors of moderate to severe chronic kidney disease in Golestan Province, northeast of IranAn international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis)Randomized Polypill crossover trial in people aged 50 and over.Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study.CARRS Surveillance study: design and methods to assess burdens from multiple perspectivesThe efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor managementThe clinical performance of an office-based risk scoring system for fatal cardiovascular diseases in North-East of Iran.[Management of different cardiovascular risk factors with a combination tablet (polypill)].Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population.Normal limit for serum alanine aminotransferase level and distribution of metabolic factors in old population of kalaleh, iran.Effects of administration of omega-3 fatty acids with or without vitamin E supplementation on adiponectin gene expression in PBMCs and serum adiponectin and adipocyte fatty acid-binding protein levels in male patients with CAD.The cardiovascular polypill in high-risk patients.New lipid-lowering drugs: an update.Population-level changes to promote cardiovascular health.A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.Atorvastatin calcium plus amlodipine for the treatment of hypertension.Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement.Advances and challenges in treatment and prevention of ischemic stroke.Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis.Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.Integrated preclinical cardiovascular prevention: a new paradigm to face growing challenges of cardiovascular disease.Hypercholesterolemia and Hypertension: Two Sides of the Same Coin.Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.Improving cardiovascular protection: focus on a cardiovascular polypill.Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension.Polypills for the prevention of Cardiovascular diseases.Expert opinion: the therapeutic challenges faced by statin intolerance.Pars cohort study of non-communicable diseases in Iran: protocol and preliminary results.Evaluation of a systematic cardiovascular disease risk reduction strategy in primary healthcare: an exploratory study from Zhejiang, China.Whole-Body Imaging Procedures in Resistant Hypertension: Evaluating for Secondary Causes or to Define End-Organ Damages?
P2860
Q24195065-9F449101-1E06-48FE-A7F7-CE024F6FC531Q26753102-F841104E-34E8-4922-B70D-E064FB96F6EAQ26999319-4A9011F3-12AA-4929-952C-72796F4D36F9Q28485196-FF328665-46C6-4B54-8F8C-731DF9B81C8DQ28546905-06B22F8C-894A-4233-AA77-FC4B71EAA5FEQ30235416-CE711D6A-1CDA-4887-AF82-A63CF8C5921BQ33588766-06D30380-6560-4015-8910-9C03D59EA7A5Q33769662-6084DC6E-BFDC-49A1-8201-F033EED8D24BQ33925329-BEF54B3B-6FF4-4D7E-9D98-7CED599AAAB0Q34240747-6E493916-AFE7-4A55-9F6D-937E3850B876Q34345933-341DD40C-6397-4BEC-B666-CD2C2FE847DFQ34366183-8929240A-C900-449C-B7A3-EE7A278B88A1Q34396399-0F52B9FF-9F68-4B95-ABFE-8FCA5EA34092Q34533125-AB9770C4-2C7A-44D1-BEA8-694637C34526Q35602493-845D2BF5-7060-4092-922A-343094022E65Q35642140-D2541B8C-9566-449E-B10B-8043169F907BQ36322893-1A5569EA-D1A8-4F25-85D2-2C1F56E60DAFQ37154445-3B7C769C-9FDD-4F72-AF0B-4E9D56F0E1BBQ37347728-474ADC60-DFA1-412C-BA2E-1B82F70FB540Q37723808-55D205E3-4D91-42C3-82BB-A777A39CAE4DQ37948516-63907BA4-9B4C-4078-91DA-99E77A8D8FF6Q37984782-7D8DE1F0-D7E7-4967-A959-BD743834D422Q38003594-EEFD0235-1294-4347-894E-568B2C5993ABQ38008634-918CAF5C-52EE-4198-B20C-6BDD894FCD36Q38058827-9F6B48AA-F7DB-4BD9-B10C-B6C29494583BQ38067324-9AFCE91D-0748-4A0A-A2E3-B8041D9598F1Q38079763-1896C6B9-4503-45C7-B021-97595DEE31F1Q38127644-5CB4104B-83CB-4863-A94F-53AE601C6EEBQ38136621-9D6F85EE-DEAC-408A-8AD0-59FDD5BDC010Q38394893-B2493F61-EC7F-402C-85B3-DF2015A7EDC3Q38430611-E1F63D04-04D2-4C8F-8DBD-DED536DBB927Q38524257-F400871E-53A1-45B3-A211-3B327844FBD7Q38615230-9E5A63CB-9A8B-4B4F-A078-A922B8A7EE44Q38664558-F79683AA-3272-4A1C-A71D-A4F39CFFEFDCQ38701607-94C2FEEE-8ED1-4B14-AC6A-6D99D603E3A0Q38809466-36EB7C6B-2BE8-473F-9D64-8E0372B48E8DQ38851603-79262184-AD61-4C95-9AA8-D9A496886B30Q39651256-46FAE05E-5745-47B2-A23A-A82325DC1133Q44197079-A23D21C7-3F47-4FC3-BF2A-C9B44FF1602FQ48290175-4DDCA1E6-3F3D-4D5A-B635-B95F1CA98B0A
P2860
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A pilot double-blind randomise ...... n cardiovascular risk factors.
@en
A pilot double-blind randomise ...... fixed-dose combination therapy
@nl
type
label
A pilot double-blind randomise ...... n cardiovascular risk factors.
@en
A pilot double-blind randomise ...... fixed-dose combination therapy
@nl
prefLabel
A pilot double-blind randomise ...... n cardiovascular risk factors.
@en
A pilot double-blind randomise ...... fixed-dose combination therapy
@nl
P2093
P2860
P50
P1476
A pilot double-blind randomise ...... on cardiovascular risk factors
@en
P2093
A Pourshams
B Larijani
F Malekzadeh
M Gharravi
R Malekzadeh
P2860
P304
P356
10.1111/J.1742-1241.2010.02412.X
P50
P577
2010-08-01T00:00:00Z